Wade, Alan G.; Fernandez, Jose-Luis; Francois, Clement; … - In: PharmacoEconomics 26 (2008) 11, pp. 969-981
Background: Selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs) are approved for the treatment of major depressive disorder (MDD). The allosteric SSRI escitalopram has been shown to be at least as clinically effective as the SNRIs venlafaxine...